A comparison between diagnostic I-123 and posttherapy I-131 scans in the detection of remnant and locoregional thyroid disease

Clinical Nuclear Medicine

Volumn 34, Issue 11, 2009, Pages 745-748

  Thomas, Damita L ^a   Menda, Yusuf ^a   Bushnell, David ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

I 123 pretherapy imaging; I 131 radioablation; Thyroid cancer

Indexed keywords

IODINE 123; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; REGIONAL METASTASIS; THYROID CANCER; THYROID DISEASE; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; COMPARATIVE STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; SCINTISCANNING; THYROID TUMOR;

ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; THYROID NEOPLASMS; YOUNG ADULT;

EID: 73449123775     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181b7dbb1     Document Type: Article

References (19)

1. Lees W, Mansberg R, Roberts R, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging. 2002;29:1421-1427.
2. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242-246.
3. Lassmann ML, Luster M, Hanscheid H, et al. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619-625.
4. Reynolds JC. Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Thyroid. 1997;7:281-284.
5. Souza Rosario PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid cancer metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795-798.
6. SNM procedure guidelines for scintigraphy for differentiated papillary and follicular thyroid cancer. Available at: www.SNM.org/PracticeManagement/ ProcedureGuidelines.
7. Amdur RJ, Mazzaferri EL. The value of a post-treatment whole body scan. In: Amdur RJ, Mazzaferri EL, eds. Essentials of Thyroid Cancer Management. Basel, Switzerland: Birkhauser; 2005:65-68.
8. de Geus-Oei LF, Oei HY, Hennemann EP, et al. Sensitivity of I-123 whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002;29:768-774.
9. Cohen J, Kalinyak J, McDougall IR. Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans. Nucl Med Commun. 2004;25:129-134.
10. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
11. Alzahrani A, Bakheet S, Al Mandil M, et al. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. J Clin Endocrinol Metab. 2001;86:5294-5300.
12. Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic imaging agent in differential thyroid carcinoma: a comparison with iodine-131 posttreatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34:1012-1017.
13. Gerard S, Cavalieri R. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27:1-8.
14. Klein HA, DiSibio KJ, Sims D, et al. I-123 whole body scanning: case report and discussion. Clin Nucl Med. 2005;30:312-316.
15. Hilditch TE, Dempsey MF, Bolster AA, et al. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging. 2002;29:783-788.
16. Sisson J, Avram AM, Lawson SA, et al. The so-called stunning of thyroid tissue. J Nucl Med. 2006;47:1406-1412.
17. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. l983;309:937-941.
18. Park SG, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during 131I scanning in patients with thyroid cancer: comparison studies with recombinant human TSH (rhTSH) vs. hypothyroidism. J Nucl Med. 1996;37(suppl):15P.
19. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371-1377.